Kaeda相关文献与解析，生知库 | 链接生命科学的每一步

Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?

诊断时 BCR-ABL/GUSB 转录水平是否可作为接受伊马替尼治疗的慢性粒细胞白血病患者的早期预测标志物？

期刊:Revista Brasileira de Hematologia e Hemoterapia

影响因子:

doi:10.1016/j.bjhh.2014.08.003

Bonecker, Simone; Magnago, Marina; Kaeda, Jaspal; Solza, Cristiana; Zalcberg Renault, Ilana

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines

Jak2 1 型抑制剂 NVP-BSK805 和 NVP-BVB808 对 Jak2 突变阳性和 Bcr-Abl 阳性细胞系的影响

期刊:Acta Haematologica

影响因子:8.2

doi:10.1159/000356784

Frauke Ringel, Jaspal Kaeda, Michaela Schwarz, Christian Oberender, Peggy Grille, Bernd Dörken, Fanny Marque, Paul W Manley, Thomas Radimerski, Philipp le Coutre

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

白血病微小残留病灶研究的必要性及其原因：欧洲白血病网络WP10和WP12工作组的综述

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2008.004267

Béné, Marie C; Kaeda, Jaspal S

白血病

发表日期：2009

文献求助收藏

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

在对伊马替尼治疗有反应的慢性期慢性粒细胞白血病患者中发现激酶结构域突变，可能有助于识别疾病进展高风险人群。

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2008.16.9953

Khorashad, Jamshid S; de Lavallade, Hugues; Apperley, Jane F; Milojkovic, Dragana; Reid, Alistair G; Bua, Marco; Szydlo, Richard; Olavarria, Eduardo; Kaeda, Jaspal; Goldman, John M; Marin, David

Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?

低剂量白细胞介素-2疗法：在实体器官移植中微调Treg细胞？

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

临床过继性调节性T细胞疗法：现状、挑战与展望

Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective

欧洲先进疗法药品转化：开发商的视角

Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?

诊断时 BCR-ABL/GUSB 转录水平是否可作为接受伊马替尼治疗的慢性粒细胞白血病患者的早期预测标志物？

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines

Jak2 1 型抑制剂 NVP-BSK805 和 NVP-BVB808 对 Jak2 突变阳性和 Bcr-Abl 阳性细胞系的影响

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

白血病微小残留病灶研究的必要性及其原因：欧洲白血病网络WP10和WP12工作组的综述

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

在对伊马替尼治疗有反应的慢性期慢性粒细胞白血病患者中发现激酶结构域突变，可能有助于识别疾病进展高风险人群。